कंपनी का अवलोकन
Xtant Medical Holdings, Inc. operates as a provider of regenerative medicine products and specialized medical devices tailored for orthopedic and neurological surgeons within the United States and international markets. The company functions within the healthcare sector, specifically under the medical devices industry, which focuses on manufacturing tools and materials essential for surgical procedures and patient rehabilitation. The firm's current market capitalization stands at $65.86M, supported by an annual revenue of $133.93M, while specific employee count data is not publicly disclosed in the available records. These valuation and revenue figures suggest that Xtant Medical holds a niche position in a specialized segment, reflecting a mid-cap status where the company's total addressable market is constrained relative to large-cap peers but offers concentrated exposure to specific surgical technologies.
वित्तीय स्वास्थ्य
The company reported a trailing twelve-month revenue of $133.93M, generating a net income of $4.97M and an EBITDA of $12.51M, illustrating a significant gap between top-line revenue and bottom-line profit that highlights the substantial cost structure required to operate in the medical device manufacturing and distribution landscape. The entity maintains a free cash flow of $6.50M, which provides a measure of financial flexibility allowing for capital expenditures, debt repayment, or potential strategic acquisitions without immediate reliance on external financing. Profitability metrics reveal a gross margin of 62.9%, indicating high pricing power or efficient production costs for its specialized bone matrix and scaffold products, while an operating margin of -2.9% suggests that operational expenses currently exceed operating income before interest and taxes. Conversely, a profit margin of 3.7% demonstrates the company's ability to convert revenue into net earnings after all expenses, interest, and taxes are accounted for. Regarding leverage, the company holds $17.05M in cash against $28.72M in total debt, resulting in a debt-to-equity ratio of 56.36, which indicates a leveraged balance sheet where debt obligations exceed equity capitalization. Liquidity is robust, evidenced by a current ratio of 2.65, meaning the company possesses more than double the current assets necessary to cover its short-term liabilities. Furthermore, the return on equity stands at 10.6% and the return on assets is 4.8%, metrics that reveal management's effectiveness in utilizing shareholders' equity and total assets to generate net income respectively.
मूल्यांकन आकलन
Valuation multiples indicate a trailing P/E ratio of 15.67 and a forward P/E of -23.51, implying that the market expects a significant expansion in future earnings or that current earnings are depressed due to non-recurring costs, leading to a negative forward multiple. The price-to-book ratio is recorded at 1.29, suggesting that the market values the company at a slight premium over its net asset book value, which is common for firms with intangible assets or specialized intellectual property in the medical sector. Alternative valuation metrics show a price-to-sales ratio of 0.49 and an EV/EBITDA of 6.20, figures that suggest the stock is priced conservatively relative to its sales volume and enterprise value compared to earnings before interest, taxes, depreciation, and amortization. Price action over the past year has ranged between a 52-week high of $0.95 and a 52-week low of $0.34, indicating a wide trading range where the current price position reflects significant volatility within this specific band. The stock exhibits a beta of -0.16, a unique negative value that implies the share price moves inversely to the broader market, displaying a volatility profile that diverges sharply from the standard positive correlation seen in most healthcare equities.
Growth & Income
Revenue growth year-over-year is recorded at 2.7%, while earnings growth year-over-year is listed as N/A, indicating that earnings expansion is currently undefined or not applicable for the comparative period provided in the dataset. The absence of a positive earnings growth rate relative to revenue suggests that the company is in a phase where top-line expansion does not yet translate directly into proportional bottom-line growth, potentially due to the lag effect of investments or restructuring costs. The company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which means all available earnings are retained within the business to fund operations and growth initiatives rather than being distributed to shareholders. Consequently, the overall growth and income profile for Xtant Medical Holdings, Inc. is characterized by capital retention and revenue expansion rather than income generation through dividends or rapid earnings acceleration.